Alaunos Therapeutics (TCRT) Change in Accured Expenses (2009 - 2026)
Alaunos Therapeutics (TCRT) reported Change in Accured Expenses of -$5000.0 for Q1 2026, down 109.09% on a YoY basis from $55000.0 in Q1 2025, and down 104.1% quarter-over-quarter from $122000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) Change in Accured Expenses (2009 - 2026) Analysis & Trends
Alaunos Therapeutics has reported Change in Accured Expenses for 18 years, with the latest figure at -$5000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 109.09% year-over-year to -$5000.0; the trailing twelve-month figure through Mar 2026 stood at -$36000.0 (up 91.26% YoY), and the FY2025 full-year result was $24000.0, up 102.06% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$5000.0, down from $122000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $1.9 million in Q3 2022, with the low at -$2.2 million in Q4 2022.
- Historically, Change in Accured Expenses has averaged -$341294.1 across 5 years, with a median of -$174000.0 in 2024.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses plunged 523.36% — and 2025, when it jumped 163.54%.
- Alaunos Therapeutics' Change in Accured Expenses stood at -$2.2 million in 2022, then increased by 21.07% to -$1.7 million in 2023, then soared by 88.91% to -$192000.0 in 2024, then soared by 163.54% to $122000.0 in 2025, then sank by 104.1% to -$5000.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$5000.0 (Q1 2026), $122000.0 (Q4 2025), and -$188000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Alaunos Therapeutics | 4.31 Mn | 3.95 Mn | - | -5,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5,000.00 |
| Mar 31, 2026 | -5,000.00 |
| Dec 31, 2025 | 122,000.00 |
| Dec 31, 2025 | 122,000.00 |
| Sep 30, 2025 | -188,000.00 |
| Sep 30, 2025 | -188,000.00 |
| Jun 30, 2025 | 35,000.00 |
| Jun 30, 2025 | 35,000.00 |
| Mar 31, 2025 | 55,000.00 |
| Mar 31, 2025 | 55,000.00 |
| Dec 31, 2024 | -192,000.00 |
| Dec 31, 2024 | -192,000.00 |
| Sep 30, 2024 | -174,000.00 |
| Sep 30, 2024 | -174,000.00 |
| Jun 30, 2024 | -101,000.00 |
| Jun 30, 2024 | -101,000.00 |
| Mar 31, 2024 | -697,000.00 |
| Mar 31, 2024 | -697,000.00 |
| Dec 31, 2023 | -1.73 Mn |
| Dec 31, 2023 | -1.73 Mn |